News for 'Sun Pharma'

Sensex, Nifty rebound nearly 1% on value buying

Sensex, Nifty rebound nearly 1% on value buying

Rediff.com16 Jun 2025

Among 30 Sensex firms, UltraTech Cement, Tech Mahindra, HCL Tech, Tata Consultancy Services, Eternal, Asian Paints, Tata Steel and Kotak Mahindra Bank were among the biggest gainers. Tata Motors, Adani Ports and Sun Pharma were the laggards.

Diabetes Drug Price Drops 90%

Diabetes Drug Price Drops 90%

Rediff.com20 Mar 2025

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.

Procter & Gamble names Shailesh Jejurikar as CEO

Procter & Gamble names Shailesh Jejurikar as CEO

Rediff.com29 Jul 2025

Procter & Gamble has announced Shailesh Jejurikar as its next CEO, effective January 1, 2026. Jejurikar, an India-born executive, will succeed Jon Moeller in the role.

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

Rediff.com20 Nov 2023

Pharmaceuticals major Mankind Pharma reported a 21 per cent year-on-year (Y-o-Y) increase in net profit, with revenue rising by 12 per cent Y-o-Y in the second quarter of the financial year 2024 (Q2FY24) in a regulatory filing lrecently.

India's pharma industry likely to take 5-6% price hikes this year

India's pharma industry likely to take 5-6% price hikes this year

Rediff.com6 Sep 2023

Notwithstanding the fact that the country's pharmaceutical (pharma) pricing regulator has allowed a 12 per cent price increase for medicines listed under the National List of Essential Medicines (NLEM) in 2023, analysts and industry insiders predict that the overall domestic pharma industry will only witness a price hike of 5-6 per cent. This is attributed to higher competitive intensity in the market. Krishnakumar V, executive director and chief operating officer (CEO) of Eris Lifesciences, a domestic-focused pharma company, noted that the NLEM segment experienced growth suppression of around 150 basis points due to price reductions during the January to July period this year.

Can India-US Tariff Issue Be Resolved Amicably?

Can India-US Tariff Issue Be Resolved Amicably?

Rediff.com28 Aug 2025

Communication channels between India and the US are open to resolve the ongoing tariff issues, and the glitch in trade ties is only temporary, given the long-term relationship between the two nations, government sources said on Wednesday. The US' 50 per cent tariffs on Indian exports to America came into effect from August 27, barring a few sectors.

LIC's stock portfolio sees Rs 46,000 cr dent in July

LIC's stock portfolio sees Rs 46,000 cr dent in July

Rediff.com5 Aug 2025

Life Insurance Corporation (LIC) , the country's largest domestic institutional investor (DII), has seen a Rs 46,000 crore erosion in the value of its equity holdings amid market downturns in July. The benchmark indices, Nifty 50 and BSE Sensex, have slipped 2.6 per cent from their June 2025-end level to 24,837 and 81,463.09 respectively.

'Will Learning AI Help Me As An Entrepreneur?'

'Will Learning AI Help Me As An Entrepreneur?'

Rediff.com28 May 2025

Dr Ganesh Natarajan, a special guest on rediffGURUS, has been addressing questions from Rediff readers, about how to grow professionally, how women can achieve leadership roles in Indian companies, and what it takes to succeed as an entrepreneur.

US Farm Distress Real Reason For Trump's Tariff Tantrums

US Farm Distress Real Reason For Trump's Tariff Tantrums

Rediff.com16 Sep 2025

'What the US appears to be doing is to force India to be "the buyer of last resort", on whom their products can be dumped, 1.4 billion people have to eat something, so why not eat American corn?' 'What is exercising the Trump lot is the fact that most of the farms are in solidly Republican Midwestern states: Illinois, Indiana, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin,' points out Rajeev Srinivasan.

Sensex gains 300 pts on fresh foreign fund inflows and buying in ICICI Bank, RIL

Sensex gains 300 pts on fresh foreign fund inflows and buying in ICICI Bank, RIL

Rediff.com27 Jun 2025

From the Sensex pack, Asian Paints, UltraTech Cement, Power Grid, ICICI Bank, Reliance Industries, Hindustan Unilever, Bharat Electronics and Sun Pharma were among the major gainers. In contrast, Trent, Eternal, Axis Bank and Titan were among the laggards.

Sensex gains 318 pts on buying in RIL, L&T

Sensex gains 318 pts on buying in RIL, L&T

Rediff.com27 Mar 2025

From the Sensex pack, Bajaj Finserv, IndusInd Bank, NTPC, Larsen & Toubro, UltraTech Cement, Adani Ports, Bajaj Finance, Power Grid, Zomato, State Bank of India, HDFC Bank and Titan were the biggest gainers. Tata Motors tanked over 5.5 per cent after US President Donald Trump announced he would impose 25 per cent tariffs on imported cars. Sun Pharma, Kotak Mahindra Bank, Bharti Airtel, HCL Tech and Mahindra & Mahindra were also among the laggards.

'Sun Pharma offers the best medium- to long-term earnings growth visibility'

'Sun Pharma offers the best medium- to long-term earnings growth visibility'

Rediff.com3 Apr 2023

India's largest listed pharmaceutical (pharma) company - Sun Pharmaceutical Industries (Sun Pharma) - is expected to maintain its outperformance vis--vis the sector's, as its multiple bets on specialty products, improving product mix, recent acquisitions, and branded business are finding favour with brokerages. While it has gained 7 per cent over the past year, the Nifty Pharma Index is down 13.6 per cent. Its outperformance over two years has been fairly evident, with the market leader gaining 66 per cent to Nifty Pharma's minus 1.4 per cent.

Sigachi used old machinery despite requests to change, says FIR

Sigachi used old machinery despite requests to change, says FIR

Rediff.com2 Jul 2025

An FIR filed against Sigachi Industries following a fatal explosion at its Telangana unit alleges the company used outdated machinery despite warnings from employees.

Key mantra for India's pharma sector in 2023

Key mantra for India's pharma sector in 2023

Rediff.com21 Dec 2022

Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership, amid emerging challenges of inflation and pricing pressures in the global markets. While R&D investment, market competitiveness, regulatory scrutiny, and domestic price regulations are expected to shape the growth of generics and injectable products, concerns such as price control and customs duties on medical equipment will continue to bother the healthcare industry in 2023. The industry believes that in view of India's G20 Presidency, digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023.

Sensex surges over 769 pts as FMCG, power shares gain

Sensex surges over 769 pts as FMCG, power shares gain

Rediff.com23 May 2025

From the Sensex firms, Eternal, Power Grid, ITC, Bajaj Finserv, Nestle, Axis Bank, Kotak Mahindra Bank and Adani Ports were among the biggest gainers. Sun Pharma was the only laggard, declining nearly 2 per cent.

Foreign fund inflows, ICICI Bank and RIL boost markets

Foreign fund inflows, ICICI Bank and RIL boost markets

Rediff.com5 Jun 2025

Eternal was the biggest gainer in the Sensex pack, jumping 4.50 per cent, followed by Power Grid, ICICI Bank, Reliance Industries, UltraTech Cement, Adani Ports, Sun Pharma, ITC and Hindustan Unilever were also among the winners. In contrast, IndusInd Bank, Axis Bank, Bajaj Finserv and Bajaj Finance were among the laggards.

Why Stock Tips Won't Build Wealth For You

Why Stock Tips Won't Build Wealth For You

Rediff.com3 Sep 2025

Real wealth isn't built on random bets; it's built on disciplined, guided portfolio strategies that can withstand market ups and downs, says Ramalingam Kalirajan.

Key factors to drive stock markets this week

Key factors to drive stock markets this week

Rediff.com6 Jul 2025

Equity investors are up for an eventful trading week ahead as the 90-day suspension period of the reciprocal tariffs announced by US President Donald Trump ends on July 9, analysts said, adding that a positive outcome from the trade negotiations could further lift market sentiment, particularly benefiting trade-sensitive sectors.

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Rediff.com19 Jun 2023

Sun Pharmaceutical Industries (Sun Pharma) reported a turnaround in the January-March quarter of the 2022-23 financial year (Q4FY23), declaring a profit after tax (PAT) of Rs 1,984 crore versus a loss of Rs 2,277 crore in Q4FY22. However, that loss in FY22 was due to several exceptional one-time items -- with Rs 3,723.15 crore allocated to settlement of lawsuits in the US and other Exceptional Items adding up to Rs 3,935.75 crore. Adjusted for exceptional items, PAT in Q4FY22 amounts to Rs 2,155 crore, which is a year-on-year (YoY) growth of about 36 per cent.

Sensex sinks 573 pts on global tensions and high crude prices

Sensex sinks 573 pts on global tensions and high crude prices

Rediff.com13 Jun 2025

Sensex sinks 573 pts on global tensions and high crude prices

Sensex ends down 182 points on selling in IT shares

Sensex ends down 182 points on selling in IT shares

Rediff.com30 May 2025

Among Sensex firms, Tech Mahindra, HCL Tech, Asian Paints, NTPC, Infosys, Nestle, Sun Pharma, and Tata Steel were the major laggards. Eternal, State Bank of India, HDFC Bank, Larsen & Toubro, Reliance Industries and Bajaj Finserv were the gainers.

Sensex drops 345 points on weakness in IT stocks

Sensex drops 345 points on weakness in IT stocks

Rediff.com10 Jul 2025

From the Sensex pack, Bharti Airtel, Asian Paints, Infosys, Bharat Electronics, Tech Mahindra and Eternal were major laggards. However, Maruti, Tata Steel, Bajaj Finance, Bajaj Finserv, Trent and Tata Consultancy Services were among the gainers.

Sensex sheds 239 pts on selling in FMCG, auto shares

Sensex sheds 239 pts on selling in FMCG, auto shares

Rediff.com28 May 2025

IndusInd Bank, Nestle, UltraTech Cement, Mahindra & Mahindra, Power Grid, Asian Paints, Sun Pharma and Tech Mahindra were also among the laggards. Bajaj Finance, Bharti Airtel, ICICI Bank, Adani Ports and HCL Tech were among the gainers.

Sun Pharma's Halol facility listed under USFDA import alert

Sun Pharma's Halol facility listed under USFDA import alert

Rediff.com8 Dec 2022

Sun Pharmaceutical Industries Ltd on Thursday said its Halol facility in Gujarat has been listed under import alert by the USFDA with products manufactured at the unit now are subject to refusal of admission in the US market. The development follows an inspection of the facility by the US Food and Drug Administration (USFDA) from April 26 to May 9, 2022. "We now wish to inform you that the company has received a communication from the USFDA stating that the facility has been listed under Import Alert," Sun Pharma said in a regulatory filing.

Trump Is Winning Tariff War Hands Down

Trump Is Winning Tariff War Hands Down

Rediff.com18 Aug 2025

Donald Trump's tariffs, meant as political punishment, have avoided the predicted chaos, lifting US growth, weakening rivals, and letting him claim victory in a resilient global economy, observes T T Ram Mohan.

Trump's Tariffs: Why India Needs To Be Strategic

Trump's Tariffs: Why India Needs To Be Strategic

Rediff.com12 Aug 2025

In trade negotiations, as in chess, sometimes you need to accept a temporary disadvantage to secure a better long-term position, points out Sonal Varma, chief economist (India and Asia ex-Japan) at Nomura.

Sensex jumps 410 pts on buying in banking shares

Sensex jumps 410 pts on buying in banking shares

Rediff.com21 May 2025

Among Sensex firms, Bajaj Finserv, Tata Steel, Sun Pharma, Tech Mahindra, Bajaj Finance, NTPC, Nestle, Tata Motors, Hindustan Unilever and Mahindra & Mahindra were the biggest gainers. IndusInd Bank, Kotak Mahindra Bank, Power Grid and ITC were among the laggards.

76 pharma firms raided, licences of 18 cancelled for manufacturing spurious drugs

76 pharma firms raided, licences of 18 cancelled for manufacturing spurious drugs

Rediff.com28 Mar 2023

In a major crackdown against the manufacture of substandard drugs, central and state regulators conducted joint inspections at 76 pharma companies and cancelled the licences of 18 of them for producing spurious and adulterated drugs, official sources said on Tuesday.

Sensex jumps 1,006 pts on buying in RIL, foreign fund inflows

Sensex jumps 1,006 pts on buying in RIL, foreign fund inflows

Rediff.com28 Apr 2025

Sun Pharma, Tata Steel, State Bank of India, Axis Bank, Tata Motors, Larsen & Toubro and ICICI Bank were also among the Sensex gainers. HCL Tech, UltraTech Cement, Nestle and Hindustan Unilever were among the laggards.

Margin pressures, growth triggers to weigh on Dr Reddy's

Margin pressures, growth triggers to weigh on Dr Reddy's

Rediff.com21 May 2025

Pharma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of financial year 2024-25 (Q4FY25), even as revenue growth remained healthy. Lower gross margin performance and muted domestic growth are key concerns. Most brokerages have a "Sell" or "Reduce" rating as there are uncertainties related to the development of a new product portfolio and the launch timelines.

Budget 2023: What the pharma, healthcare industry seek

Budget 2023: What the pharma, healthcare industry seek

Rediff.com19 Jan 2023

The government should take measures to promote innovation and R&D while simplifying regulations for the sector in the upcoming Union Budget, as per pharmaceutical industry bodies. Outlining the wish list for the sector in the upcoming Union Budget, Indian Pharmaceutical Alliance (IPA) secretary general Sudarshan Jain said the domestic pharma industry is currently around $50 billion in size and aspires to grow to around $130 billion by 2030 and $450 billion by 2047. "To achieve this vision, the Union Budget 2023-2024 should help fuel innovation and R&D, which will set the pace for propelling the pharmaceutical industry forward," he told PTI.

3 Indian pharma cos recall products in US market

3 Indian pharma cos recall products in US market

Rediff.com24 Apr 2022

Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons, as per the latest enforcement report by the US Food and Drug Administration (USFDA). While Aurobindo Pharma is recalling Cyanocobalamin Injection, which is used to treat and prevent lack of vitamin B12, Mumbai-based Sun Pharma is recalling a drug used to increase the production of natural tears in eyes. Similarly, Jubilant Cadista is recalling a drug which is used to treat different inflammatory conditions.

Uncertain future awaits Indian pharma exporters

Uncertain future awaits Indian pharma exporters

Rediff.com25 Aug 2021

As uncertainty looms large in Afghanistan, Indian pharma exporters are apprehensive to send goods to the war-torn country and the target of exporting $126 million worth of pharmaceutical goods to the Taliban-ruling nation now depends on the future outcome. Udaya Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (Pharmexcil) body under the Department of Commerce on Tuesday said as the situation is grim over there and India pharma exporters have cordial relations with Afghanistan. "The projected target for 2021-22 is $126.22 million.

Exports inch up; trade deficit hits $21.54 bn in March

Exports inch up; trade deficit hits $21.54 bn in March

Rediff.com16 Apr 2025

India's exports grew marginally by 0.7 per cent to $41.97 billion in March, while the trade deficit stood at $21.54 billion in the month, the latest government data showed on Tuesday.

Pharma stocks rally on lower price erosion, hopes of US generic mkt uptick

Pharma stocks rally on lower price erosion, hopes of US generic mkt uptick

Rediff.com9 Jul 2023

The BSE Healthcare Index is up 19 per cent as compared to BSE Sensex returns of 11 per cent during this period. Nitin Agarwal of DAM Capital highlighted this trend in a report last month. "After a sustained period of underperformance over FY21-23, the BSE Healthcare Index has once again captured the spotlight. "The recent uptick in performance has been driven by hospitals and emerging green shoots in pharmaceutical exports, particularly to the US, along with sustaining momentum in domestic branded formulations," he said.

Markets slump over 1%; Sensex tanks 1,282 points

Markets slump over 1%; Sensex tanks 1,282 points

Rediff.com13 May 2025

From the Sensex firms, Infosys declined by 3.54 per cent. Power Grid, Eternal, HCL Tech, Tata Consultancy Services, Bharti Airtel, IndusInd Bank, NTPC and HDFC Bank were the major laggards. Sun Pharma, Adani Ports, Bajaj Finance, State Bank of India and Tech Mahindra were the gainers.

Domestic pharma market grew by 6.8% in 2023

Domestic pharma market grew by 6.8% in 2023

Rediff.com22 Jan 2024

The Indian pharmaceutical market (IPM) grew 6.8 per cent to touch a turnover of ~1.93 trillion in calendar year 2023, despite volumes going down marginally by 0.9 per cent. This indicates the price increase has been the major growth driver. Growth in the moving annual turnover (the previous 12 months' turnover) in December was 5.1 per cent and that in new product introduction 2.6 per cent, while volumes dipped 0.9 per cent, leading to an overall growth rate of 6.8 per cent, according to the data from market research firm Pharmatrac.

India hasn't accepted UK 'data exclusivity' demand in FTA

India hasn't accepted UK 'data exclusivity' demand in FTA

Rediff.com12 May 2025

India has not accepted the demand of the UK for inclusion of a 'data exclusivity' provision in the free trade agreement, announced on May 6, in a bid to protect the interests of the domestic generic drugs industry, an official said. During the negotiations, the UK had asked to include this provision in the trade pact.

How Kerala Aims to Be India's First Poverty Free State

How Kerala Aims to Be India's First Poverty Free State

Rediff.com14 Jul 2025

Despite facing financial constraints, Kerala has been able to invest in welfare schemes and targeted programmes.

Jurassic World Rebirth Review: Time Pass

Jurassic World Rebirth Review: Time Pass

Rediff.com4 Jul 2025

As a nothing-better-to-do weekend watch, Jurassic World Rebirth is fine. But the franchise is losing steam, observes Deepa Gahlot.